Caris Life Sciences (CAI) Short term Debt (2024 - 2026)

Caris Life Sciences (CAI) posted quarterly Short term Debt of $173000.0 for Q1 2026, up 2.37% quarter-over-quarter from $169000.0 in Q4 2025.

Caris Life Sciences (CAI) Short term Debt (2024 - 2026) Analysis & Trends

Caris Life Sciences' Short term Debt history runs 3 years deep, the most recent figure standing at $173000.0 for Q1 2026.

In Q1 2026, Short term Debt changed N/A year-over-year to $173000.0; the TTM figure through Mar 2026 stood at $173000.0 (changed N/A YoY), while the FY2025 annual figure was $169000.0, down 99.72% from the prior year.
Short term Debt for Q1 2026 stood at $173000.0, up from $169000.0 in the prior quarter.
The five-year high for Short term Debt was $60.1 million in Q4 2024, with the low at $95000.0 in Q2 2025.
The 3-year median for Short term Debt is $169000.0 (2025), against an average of $12.1 million.
Peak annual rise in Short term Debt reached 99.72% in 2025, while the deepest fall reached 99.72% in 2025.
Caris Life Sciences' Short term Debt stood at $60.1 million in 2024, then plunged by 99.72% to $169000.0 in 2025, then increased by 2.37% to $173000.0 in 2026.
Business Quant data shows CAI's Short term Debt at $173000.0 in Q1 2026, $169000.0 in Q4 2025, and $164000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Caris Life Sciences	6.16 Bn	5.37 Bn	182.38 Mn

Download Data